Press Resease

Generic Oncology Drugs Market by Molecule (Large and Small), by Administration Route (Oral and Parenteral), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 17-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 120 Report Code: ZMR-4440 Status : Published

Global generic oncology drugs market expected to generate around USD 27,815 million by 2025, at a CAGR of 6.3% between 2019 and 2025. The Asia Pacific generic oncology drugs market is expected to register a high rate of growth in the future and present important income generating possibilities for drug manufacturing companies.

Description

The report covers a forecast and an analysis of the global generic oncology drugs market on a global and regional level. The study provides historical data for 2017 and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the global generic oncology drugs market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the global generic oncology drugs market on a global level.

In order to give the users of this report a comprehensive view of the global generic oncology drugs market. We have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the global generic oncology drugs market is segmented on the basis of molecule, administration route, distribution channel, and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some major companies in the global generic oncology drugs market are Amgen, Bayer Healthcare, Teva Pharmaceutical, Boehringer Ingelheim, Pfizer, AstraZeneca, Eli Lily and Company, Hoffmann-La Roche, ARIAD Pharmaceuticals, CELGENE Corporation, GlaxoSmithKline, Novartis, Johnson and Johnson, Merck, AbbVie, and Sanofi.

This report segments the global generic oncology drugs market into:

Global Generic Oncology Drugs Market: Molecule Analysis

  • Large Molecule
  • Small Molecule

Global Generic Oncology Drugs Market: Administration Route Analysis

  • Oral
  • Parenteral

Global Generic Oncology Drugs Market: Distribution Channel Analysis

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Generic Oncology Drugs Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Generic Oncology Drugs market, 2017-2025 (USD Million)
    • 2.2. Global Generic Oncology Drugs Market: Snapshot
  •  
  • Chapter 3. Global Generic Oncology Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Cancer Incidences
      • 3.2.2. Growing R&D Spending
      • 3.2.3. Favorable Reimbursement Scenario in Developed Countries
      • 3.2.4. Increasing demand for Generic Oncology Drugs
    • 3.3. Market Restraints
      • 3.3.1. Side Effects of Cancer Drugs
      • 3.3.2. Low Affordability in Developing Countries
      • 3.3.3. Low Awareness about Generic Oncology Drugs
    • 3.4. Opportunities
      • 3.4.1. Strategic Alliances formed by Generic Oncology Drugs Companies
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Molecule
      • 3.6.2. Market attractiveness analysis, by Administration Route
      • 3.6.3. Market attractiveness analysis, by Distribution Channel
      • 3.6.4. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Generic Oncology Drugs Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Generic Oncology Drugs Market: Company Market Share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Generic Oncology Drugs Market - Molecule analysis
    • 5.1. Global Generic Oncology Drugs Market: Molecule overview
      • 5.1.1. Global Generic Oncology Drugs Market Revenue Share, by Molecule, 2018 and 2025
    • 5.2. Large Molecule
      • 5.2.1. Global Generic Oncology Drugs Market for Large Molecule, 2017-2025 (USD Million)
    • 5.3. Small Molecule
      • 5.3.1. Global Generic Oncology Drugs Market for Small Molecule, 2017-2025 (USD Million)
  •  
  • Chapter 6. Global Generic Oncology Drugs Market - Administration Route Analysis
    • 6.1. Global Generic Oncology Drugs Market: Administration Route
      • 6.1.1. Global Generic Oncology Drugs Market Revenue Share, by Administration Route, 2018 and 2025
    • 6.2. Oral
      • 6.2.1. Global Generic Oncology Drugs Market for Oral, 2017-2025 (USD Million)
    • 6.3. Parenteral
      • 6.3.1. Global Generic Oncology Drugs Market for Parenteral, 2017-2025 (USD Million)
  •  
  • Chapter 7. Global Generic Oncology Drugs Market - Distribution Channel Analysis
    • 7.1. Global Generic Oncology Drugs Market Distribution Channel
      • 7.1.1. Global Generic Oncology Drugs Market Revenue Share, by Distribution Channel, 2018 and 2025
    • 7.2. Hospital Pharmacy
      • 7.2.1. Global Generic Oncology Drugs Market for Hospital Pharmacy, 2017-2025 (USD Million)
    • 7.3. Retail Pharmacy
      • 7.3.1. Global Generic Oncology Drugs Market for Retail Pharmacy, 2017-2025 (USD Million)
    • 7.4. Online Pharmacy
      • 7.4.1. Global Generic Oncology Drugs Market for Online Pharmacy, 2017-2025 (USD Million)
  •  
  • Chapter 8. Global Generic Oncology Drugs Market - Regional Analysis
    • 8.1. Global Generic Oncology Drugs Market: Regional Overview
      • 8.1.1. Global Generic Oncology Drugs Market Revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.2.2. North America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.2.3. North America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.2.4.2. The U.S. Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.2.4.3. The U.S. Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.2.5.2. Rest of North America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.2.5.3. Rest of North America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.3.2. Europe Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.3.3. Europe Generic Oncology Drugs Market Revenue, by End -User, 2017-2025 (USD Million)
      • 8.3.4. UK
        • 8.3.4.1. UK Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.4.2. UK Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.4.3. UK Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.5.2. Germany Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.5.3. Germany Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.6.2. France Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.6.3. France Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.3.7.3. Rest of Europe Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.4.2. Asia Pacific Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.4.3. Asia Pacific Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.4.2. China Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.4.3. China Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.5.2. Japan Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.5.3. Japan Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.6.2. India Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.6.3. India Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.5.2. Latin America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.5.3. Latin America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.5.4.2. Brazil Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.5.4.3. Brazil Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Molecule, 2017-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Generic Oncology Drugs Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Amgen
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Molecule portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Bayer Healthcare
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Molecule portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Teva Pharmaceutical Industries
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Molecule portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Boehringer Ingelheim
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Molecule portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Pfizer
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Molecule portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. AstraZeneca
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Molecule portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Eli Lily and Company
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Molecule portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Hoffmann-La Roche
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Molecule portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. ARIAD Pharmaceuticals
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Molecule portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. CELGENE Corporation
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Molecule portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. GlaxoSmithKline
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Molecule portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Novartis
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Molecule portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments
    • 9.13. Johnson and Johnson
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Molecule portfolio
      • 9.13.4. Business strategy
      • 9.13.5. Recent developments
    • 9.14. Merck
      • 9.14.1. Overview
      • 9.14.2. Financials
      • 9.14.3. Molecule portfolio
      • 9.14.4. Business strategy
      • 9.14.5. Recent developments

Methodology

Free Analysis

Branded oncology drugs are bioequivalent to generic drugs in dosage form, quality, strength, intended use, and administration route. After the expiry of the specific patent, any other manufacturer can copy and produce the same branded drugs at an affordable cost. The key advantage of generic drugs is that they are less expensive than branded drugs as they don't have to go through expensive clinical trial stages and pay for marketing, advertising, and promotion. Generic drugs should have the same active ingredient, the same administration route, the same dosage strength, and form as per FDA rules and regulations for branded drug substitution.

The two main growth factors expected to drive the generic oncology drugs market in the future are increasing expenditure on cancer-related research and development activities by multiple governments and private and commercial organizations and rising investments for anti-cancer drugs. It is anticipated that a notable product pipeline will drive profitable possibilities for generic oncology drugs market in the years ahead. Furthermore, with the industry pipeline achieving a historic level of late-stage growth, the generic oncology drugs market is expected to grow notably. The increasing research activities for oncology drugs by key companies operating in the generic oncology drugs market and a large number of pipeline products are also boosting the market globally. These companies are majorly focusing on developing generic forms of oncology drugs.

The global generic oncology drugs market is fragmented on the basis of molecule, administration route, and distribution channel. By molecule, the global generic oncology drugs market includes small and large molecules. Based on administration route, the global market includes oral and parenteral. The distribution channel segment of the generic oncology drugs market comprises hospital pharmacy, retail pharmacy, and online pharmacy.

The Asia Pacific generic oncology drugs market is expected to register a high rate of growth in the future and present important income generating possibilities for drug manufacturing companies. Increasing research and development activities related to biological and targeted drug therapies, early expiry of patents, and rising concentration on personalized therapy medication are some key factors contributing to the Asia Pacific market for generic oncology drugs. However, strict laws concerning drug discovery and development process in Japan could limit the regional market for generic oncology drugs.

Some major companies in the global generic oncology drugs market are Amgen, Bayer Healthcare, Teva Pharmaceutical, Boehringer Ingelheim, Pfizer, AstraZeneca, Eli Lily and Company, Hoffmann-La Roche, ARIAD Pharmaceuticals, CELGENE Corporation, GlaxoSmithKline, Novartis, Johnson and Johnson, Merck, AbbVie, and Sanofi.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com